These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1530700)

  • 1. Hepatotoxicity of fluorouracil with N-phosphonacetyl-L-aspartate.
    Stenram U
    Ann Intern Med; 1992 Jul; 117(1):90-1. PubMed ID: 1530700
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study.
    Martino RL; Fleming TR; Morrell LM; Ardalan B; Richman SP; Macdonald JS
    Invest New Drugs; 1996; 14(4):419-21. PubMed ID: 9157080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
    Rosvold E; Schilder R; Walczak J; DiFino SM; Flynn PJ; Banerjee TK; Heim WJ; Engstrom PF; Ozols RF; O'Dwyer PJ
    Cancer Chemother Pharmacol; 1992; 29(4):305-8. PubMed ID: 1537077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
    Fleming RA; Capizzi RL; Muss HB; Smith S; Fernandes DJ; Homesley H; Loggie BW; Case L; Morris R; Russell GB; Richards F
    Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
    Jodrell DI; Oster W; Kerr DJ; Canney PA; Yosef H; Steward WP; Kaye SB; Cassidy J
    Eur J Cancer; 1994; 30A(7):950-5. PubMed ID: 7946590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma.
    O'Connell MJ; Moertel CG; Rubin J; Hahn RG; Kvols LK; Schutt AJ
    J Clin Oncol; 1984 Oct; 2(10):1133-8. PubMed ID: 6491697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.
    Köhne CH; Harstrick A; Hiddemann W; Schöffski P; Wilke H; Bokemeyer C; Dörken B; Schmoll HJ
    Eur J Cancer; 1997 Oct; 33(11):1896-9. PubMed ID: 9470854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of N-(phosphonacetyl)-L-aspartate + fluorouracil in clinical trials.
    Martin DS; Kemeny NE
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):228-33. PubMed ID: 1557654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
    Ardalan B; Singh G; Silberman H
    J Clin Oncol; 1988 Jun; 6(6):1053-8. PubMed ID: 3373260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data.
    Machover D
    Bull Cancer; 1994 Dec; 81 Suppl 2():74s-77s. PubMed ID: 7727863
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of PALA on the pharmacokinetics of 5-fluorouracil.
    Nassim MA; Rouini MR; Cripps MC; Shirazi FH; Veerasinghan S; Molepo JM; Obrocea M; Redmond D; Bates S; Fry D; Stewart DJ; Goel R
    Oncol Rep; 1998; 5(1):217-21. PubMed ID: 9458325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical modulation of 5-fluorouracil by PALA.
    O'Dwyer PJ
    Cancer Invest; 1990; 8(2):261-2. PubMed ID: 2400945
    [No Abstract]   [Full Text] [Related]  

  • 13. Sparfosate. A novel biomodulator of 5-fluorouracil.
    Koshland P; Maa L; Ignoffo R
    Cancer Pract; 1999; 7(4):212-6. PubMed ID: 10687588
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
    Erlichman C; Donehower RC; Speyer JL; Klecker R; Chabner BA
    J Natl Cancer Inst; 1982 Feb; 68(2):227-31. PubMed ID: 6950156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
    O'Dwyer PJ; Paul AR; Walczak J; Weiner LM; Litwin S; Comis RL
    J Clin Oncol; 1990 Sep; 8(9):1497-503. PubMed ID: 2391557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
    Buroker TR; Moertel CG; Fleming TR; Everson LK; Cullinan SA; Krook JE; Mailliard JA; Marschke RF; Klaassen DJ; Laurie JA
    J Clin Oncol; 1985 Dec; 3(12):1624-31. PubMed ID: 2933492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
    Casper ES; Vale K; Williams LJ; Martin DS; Young CW
    Cancer Res; 1983 May; 43(5):2324-9. PubMed ID: 6831457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
    Kemeny N; Schneider A; Martin DS; Colofiore J; Sawyer RC; Derby S; Salvia B
    Cancer Res; 1989 Aug; 49(16):4636-9. PubMed ID: 2472883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity.
    Kemeny NE; Schneider A; Martin DS
    Cancer Invest; 1990; 8(2):263-4. PubMed ID: 2400946
    [No Abstract]   [Full Text] [Related]  

  • 20. Biochemical modulation: application of laboratory models to the clinic.
    Leyland-Jones B; O'Dwyer PJ
    Cancer Treat Rep; 1986 Jan; 70(1):219-29. PubMed ID: 3510736
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.